Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891963550> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2891963550 abstract "4544 Background: RX-3117 is an oral small molecule antimetabolite, cyclopentyl pyrimidyl nucleoside that is activated by uridine cytidine kinase 2. RX-3117 has shown efficacy in xenograft models of gemcitabine resistant pancreatic, bladder and colorectal cancer. Preliminary data from an analysis of a phase 1b/2a clinical study of RX3117 in metastatic bladder cancer is described. Methods: This phase 1b/2a study (NCT02030067) was designed to evaluate safety, tolerability and efficacy following treatment with 700 mg administered orally once-daily for 5 consecutive days with 2 days off per week for 3 weeks with 1 week off in each 4 week cycle in a 2-stage design. Eligible subjects (aged ≥ 18 years) were those with relapsed/refractory metastatic bladder cancer with any number of prior therapies. Prior therapy with platinum-based chemotherapy was required. The primary endpoint was to assess the efficacy and safety of RX-3117 in metastatic bladder cancer, with secondary aims of evaluating PFS and CBR. Results: With 9 subjects enrolled, median age was 66 years, ECOG PS was 0-1. All subjects had received gemcitabine/cisplatin in the perioperative or metastatic setting, and 4 subjects had received 3 or more prior therapies. The most frequent related adverse events were anemia, mild-moderate fatigue, vomiting and diarrhea. No dose limiting toxicities were observed. PFS and CBR will be presented at the meeting, as 5 subjects continue to receive therapy at the time of this submission. One subject continues on treatment at 139 days with persistent stable disease. Molecular profiling of his bladder tumor showed alterations in ARID1A, FBXW7, FGFR3, NF1, and TERT. The patient previously responded to an FGFR3 inhibitor but progressed after 9 months, with ctDNA assessments showing incurrence of TP53 alteration. Clinical benefit with RX-3117 was achieved in spite of incurrence of this alteration. Conclusions: RX-3117 demonstrated an excellent safety profile, and prolonged stable disease was seen in 1 subject who failed prior cisplatin/gemcitabine and FGFR3 inhibition. Activity persisted despite development a putative resistance alteration detected by ctDNA. Clinical trial information: NCT02030067." @default.
- W2891963550 created "2018-09-27" @default.
- W2891963550 creator A5007663088 @default.
- W2891963550 creator A5013942253 @default.
- W2891963550 creator A5019792338 @default.
- W2891963550 creator A5022022603 @default.
- W2891963550 creator A5032034522 @default.
- W2891963550 creator A5034354367 @default.
- W2891963550 creator A5041033274 @default.
- W2891963550 creator A5084571872 @default.
- W2891963550 creator A5090179091 @default.
- W2891963550 date "2017-05-20" @default.
- W2891963550 modified "2023-09-27" @default.
- W2891963550 title "Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ia/IIb study." @default.
- W2891963550 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.4544" @default.
- W2891963550 hasPublicationYear "2017" @default.
- W2891963550 type Work @default.
- W2891963550 sameAs 2891963550 @default.
- W2891963550 citedByCount "0" @default.
- W2891963550 crossrefType "journal-article" @default.
- W2891963550 hasAuthorship W2891963550A5007663088 @default.
- W2891963550 hasAuthorship W2891963550A5013942253 @default.
- W2891963550 hasAuthorship W2891963550A5019792338 @default.
- W2891963550 hasAuthorship W2891963550A5022022603 @default.
- W2891963550 hasAuthorship W2891963550A5032034522 @default.
- W2891963550 hasAuthorship W2891963550A5034354367 @default.
- W2891963550 hasAuthorship W2891963550A5041033274 @default.
- W2891963550 hasAuthorship W2891963550A5084571872 @default.
- W2891963550 hasAuthorship W2891963550A5090179091 @default.
- W2891963550 hasConcept C121608353 @default.
- W2891963550 hasConcept C126322002 @default.
- W2891963550 hasConcept C143998085 @default.
- W2891963550 hasConcept C185592680 @default.
- W2891963550 hasConcept C2776543447 @default.
- W2891963550 hasConcept C2777333352 @default.
- W2891963550 hasConcept C2778397455 @default.
- W2891963550 hasConcept C2780258809 @default.
- W2891963550 hasConcept C2780352672 @default.
- W2891963550 hasConcept C71240020 @default.
- W2891963550 hasConcept C71924100 @default.
- W2891963550 hasConcept C98274493 @default.
- W2891963550 hasConceptScore W2891963550C121608353 @default.
- W2891963550 hasConceptScore W2891963550C126322002 @default.
- W2891963550 hasConceptScore W2891963550C143998085 @default.
- W2891963550 hasConceptScore W2891963550C185592680 @default.
- W2891963550 hasConceptScore W2891963550C2776543447 @default.
- W2891963550 hasConceptScore W2891963550C2777333352 @default.
- W2891963550 hasConceptScore W2891963550C2778397455 @default.
- W2891963550 hasConceptScore W2891963550C2780258809 @default.
- W2891963550 hasConceptScore W2891963550C2780352672 @default.
- W2891963550 hasConceptScore W2891963550C71240020 @default.
- W2891963550 hasConceptScore W2891963550C71924100 @default.
- W2891963550 hasConceptScore W2891963550C98274493 @default.
- W2891963550 hasLocation W28919635501 @default.
- W2891963550 hasOpenAccess W2891963550 @default.
- W2891963550 hasPrimaryLocation W28919635501 @default.
- W2891963550 hasRelatedWork W1524820710 @default.
- W2891963550 hasRelatedWork W181804983 @default.
- W2891963550 hasRelatedWork W1820069540 @default.
- W2891963550 hasRelatedWork W2020774281 @default.
- W2891963550 hasRelatedWork W2021333778 @default.
- W2891963550 hasRelatedWork W2068581230 @default.
- W2891963550 hasRelatedWork W2092057012 @default.
- W2891963550 hasRelatedWork W2108798437 @default.
- W2891963550 hasRelatedWork W2119596897 @default.
- W2891963550 hasRelatedWork W2139898001 @default.
- W2891963550 hasRelatedWork W2142485373 @default.
- W2891963550 hasRelatedWork W2166710064 @default.
- W2891963550 hasRelatedWork W2234785744 @default.
- W2891963550 hasRelatedWork W2290264682 @default.
- W2891963550 hasRelatedWork W2336100460 @default.
- W2891963550 hasRelatedWork W2338853933 @default.
- W2891963550 hasRelatedWork W2598414332 @default.
- W2891963550 hasRelatedWork W2913157672 @default.
- W2891963550 hasRelatedWork W2947036130 @default.
- W2891963550 hasRelatedWork W39975430 @default.
- W2891963550 isParatext "false" @default.
- W2891963550 isRetracted "false" @default.
- W2891963550 magId "2891963550" @default.
- W2891963550 workType "article" @default.